ImmunoVec vs Saluda Medical
Side-by-side comparison of AI visibility scores, market position, and capabilities
Received up to $40.7M ARPA-H award (Oct 2025). Polymeric nanoparticle platform to reprogram immune cells in vivo without viral vectors. Non-viral delivery for CAR-T-like therapies.
About
ImmunoVec is developing a non-viral polymeric nanoparticle delivery platform for in vivo immune cell engineering — programming a patient's immune cells directly inside their body without the expensive ex vivo manufacturing process that makes CAR-T therapies cost $500,000-$1,000,000 per treatment. The company received a selective ARPA-H (Advanced Research Projects Agency for Health) award of up to $40.7 million in October 2025 for development of its platform.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
About
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.